Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Efficacy and Safety of ALT-801 in the Treatment of Obesity

ClinicalTrials.gov ID: NCT05295875

Public ClinicalTrials.gov record NCT05295875. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 25, 2026, 10:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled and Parallel Group 48-Week Study to Evaluate the Efficacy and Safety of ALT-801 in the Treatment of Obesity (MOMENTUM Trial)

Study identification

NCT ID
NCT05295875
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Altimmune, Inc.
Industry
Enrollment
391 participants

Conditions and interventions

Interventions

  • ALT-801 Drug
  • Placebo Other

Drug · Other

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 30, 2022
Primary completion
Sep 27, 2023
Completion
Sep 27, 2023
Last update posted
Nov 28, 2023

2022 – 2023

United States locations

U.S. sites
31
U.S. states
18
U.S. cities
28
Facility City State ZIP Site status
Altimmune CTM Birmingham Alabama 35020
Altimmune CTM Mesa Arizona 85201
Altimmune CTM Los Angeles California 90001
National Research Institute Los Angeles California 90057
Altimmune CTM Montclair California 91763
Altimmune CTM Santa Barbara California 93101
Altimmune CTM Boca Raton Florida 33427
Altimmune CTM Clearwater Florida 33755
Altimmune CTM Fort Myers Florida 33900
Altimmune CTM Jacksonville Florida 32201
Altimmune CTM Port Orange Florida 32123
Altimmune CTM Sunrise Florida 33319
Altimmune CTM Savannah Georgia 31411
Altimmune CTM Evanston Illinois 60201
Altimmune CTM Indianapolis Indiana 46201
Midwest Institute for Clinical Research Indianapolis Indiana 46260
Altimmune CTM Louisville Kentucky 40202
Altimmune CTM Baton Rouge Louisiana 70801
Altimmune CTM New Orleans Louisiana 70119
Altimmune CTM Kansas City Missouri 64101
Altimmune CTM Butte Montana 59701
Altimmune CTM Berlin New Jersey 08009
Altimmune CTM New York New York 10001
Cornell University, Joan and Sanford Weill Medical College New York New York 10065
Altimmune CTM Cincinnati Ohio 45201
Altimmune CTM Philadelphia Pennsylvania 19092
Altimmune CTM Knoxville Tennessee 37901
Altimmune CTM Austin Texas 78701
Altimmune CTM Bellaire Texas 77401
Altimmune CTM San Antonio Texas 78201
Altimmune CTM St. George Utah 84770

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05295875, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 28, 2023 · Synced Jul 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05295875 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →